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ABBREVIATIONS 
 
AC  adenylate cyclase 
AcOH  acetic acid 
AMP  adenosine monophosphate 
BRET  bioluminescence resonance energy transfer 
BSA  bovine serum albumin 
cAMP  cyclic AMP 
cDNA  complementary DNA 
CE  cation exchange 
CNS  central nervous system 
cpm  count pre minute 
CRE  cAMP responsive element 
Da  Dalton 
DMEM  Dulbecco’s modified eagle medium 
DNA  deoxyribonucleic acid 
EDTA  ethylenediaminetetraacetic acid 
FBS  fetal bovine serum 
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GFP  green fluorescent protein 
GI tract  gastrointestinal tract 
GPCR  G protein-coupled receptor 
G protein GTP-binding protein 
GTP  guanosine triphosphate 
HPLC  high performance liquid chromatography 
ICP-MS  inductively coupled plasma-MS 
Luc  luciferase 
MAP kinase mitogen activated protein kinase 
MM  multi-mode 
mRNA  messenger RNA 
MS  mass spectrometry 
NTS  neurotensin 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PKA  protein kinase A 
PLC  phospholipase C 
ppb  parts per billion 
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PTx  pertussis toxin 
RhoGEF  Rho guanine nucleotide exchanging factor 
RLuc  Renilla luciferase 
RNA  ribonucleic acid 
rpm  revolution per minute 
RT-PCR  reverse transcription-PCR 
SDS  sodium dodecyl sulphate 
S.E.  standard error 
SRE  serum responsive element 
TFA  trifluoroacetic acid 
YFP  yellow fluorescent protein 
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CHAPTER Ⅰ. PREFACE 
 
 G protein-coupled receptor (GPCR) is one of the largest superfamily of 
transmembrane proteins. Based on the similarities in amino acid sequence, they are classified 
as 6 groups, rhodopsin like (class A), secretin (class B), metabotropic glutamate (class C), 
fungal mating pheromone (class D), cAMP (class E) and frizzled/smoothened (class F) 
receptors. Commonly, GPCRs have 7 transmembrane domains and work as receptors that 
transduce extracellular signals into intracellular signals.  
 Generally, GPCRs are residing in the plasma membrane and form complexes with 3 
subunits of intracellular G proteins called G, G and G. When a GPCR senses the 
extracellular signals, it makes conformational change so that the complex is disassembled. The 
G subunits dissociated from the complexes act on the effectors that transduce intracellular 
signals. The signals triggered by GPCR depend on the types of Gsubunit involved. In 
mammals, 16 types of G subunits are known, and most of them are classified as four groups, 
Gq/11, G12/13, Gs, and Gi/o. Gq/11 activates phospholipase C (PLC) to mobilize 
intracellular calcium. G12/13activates various kinds of MAP kinases thorough the activation of 
RhoGEF. Gs activates adenylate cyclase (AC) to increase intracellular cyclic AMP (cAMP), 
while Gi/o inhibits AC to reduce cAMP.  
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 Extracellular molecules that bind to GPCRs and activate them are called ligands. 
Ligands include many types of molecules such as proteins, peptides, nucleotides, lipids, amine 
derivatives, and so on. Most of them are hormones that regulate physiological functions and 
play important roles in central nervous system (CNS), immune system, metabolism, circulation, 
and so forth. Also, it is known that many GPCR signals are known to be involved in incidence 
or progression of common diseases. Exogenously-administered molecules that modify these 
signals can be therapeutic drugs and GPCR is thought to be one of the most successful 
molecular classes for drug target. Indeed, 36% of marketed drugs are targeted on GPCRs (1). 
Therefore, GPCRs have been subjects of considerable research interest by pharmaceutical 
companies and academic institutes. 
 Up to this time, there still remain many GPCRs whose ligands and functions are 
unknown. They are called “orphan” GPCRs. Exploration of the endogenous ligands of orphan 
GPCRs are called deorphanization. From 1990s to 2000s, many deorphanizations were 
demonstrated and opened new frontier of physiology. For instance, in 1999, Kangawa and his 
colleagues found ghrelin as a ligand of the growth hormone secretagogue receptor (GHSR) (2). 
Their findings gave a new understanding on appetite control of mammals. 
 In the present study, the focus is put on G protein-coupled receptor 39 (GPR39), an 
orphan GPCR. GPR39 is classified as a member of the ghrelin receptor family in class A 
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GPCRs, based on its amino acid sequence (3). Due to its expression patterns and the phenotypes 
of genetically engineered models, GPR39 is thought to have crucial roles in metabolism and 
nutrient intake. 
The translational product of the GPR39 gene is known to have two isoforms, 
GPR39-1a and GPR39-1b (4). As shown in Fig. 1, GPR39-1a is a full-length 7-transmembrane 
receptor, while GPR39-1b is a 5-transmembrane protein. Assuming from the structure, 
GPR39-1a may retain functions as a GPCR. On the other hand, it is unpredictable whether if 
GPR39-1b has functions as GPCRs, since it lacks TMⅥ, Ⅶ, and C-terminal domains that are 
crucial for functions of GPCRs.  
The purpose of the present study is to clarify the molecular functions of these two 
isoforms in order to provide a clue to understand the physiological significance of the GPR39 
gene. In the Chapter 2, the natural ligands of GPR39-1a were explored from fetal bovine serum 
(FBS) using liquid chromatography and mass spectrometry. In the Chapter 3, the molecular 
function of GPR39-1b was explored using Bioluminescence Resonance Energy Transfer 
(BRET) system, noticing interaction between GPR39-1b and other GPCRs. 
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Fig. 1 Schematic illustration of the gene structure of GPR39-1a and GPR39-1b. 
Each transcript is put with the 5’-terminus on the left and 3’-terminus on the right. Colored thick 
bars and boxes correspond to the coding regions and transmembrane domains respectively. The 
Roman numeral on each box refers to its number from the C-terminus of each protein product. 
Dotted lines indicate the regions retaining identical sequences. mRNA for GPR39-1a consists of 
two exons and the product of it contains 7 transmembrane domains. Meanwhile, the mRNA for 
GPR39-1b consists of single exon and the product of it contains 5 transmenbrane domains.  
 
1 2 
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CHAPTER Ⅱ. ISOLATION OF Zn2+ AS AN 
ENDOGENOUS AGONIST OF GPR39-1a FROM 
FETAL BOVINE SERUM 
 
1. Summary 
In this chapter, determination of the natural agonists of GPR39-1a from fetal bovine 
serum (FBS) is attempted. FBS was conditioned to extract peptides and fractionated by two 
types of HPLC. The activity of each fraction was monitored by intracellular calcium 
mobilization. Then the purified active ingredient was analyzed by inductively coupled plasma 
mass spectrometry (ICP-MS). In this fashion, Zn
2+
 ion was identified as an agonist of 
GPR39-1a, though no peptidergic molecules were found. The calcium-mobilizing activity of 
Zn
2+
 was not abolished by pertussis toxin, but was by a phospholipase C (PLC) inhibitor, 
U73122, indicating that the activity of GPR39-1a is mediated through the Gqα-PLC pathway. 
In addition, Zn
2+
 also activated mouse and rat GPR39-1a, showing that the function of 
GPR39-1a as a Zn
2+
 receptor is conserved across species. This study is the first exploration of 
GPR39-1a agonists in FBS, and indicates that GPR39-1a functions as a Gq-coupled 
Zn
2+
-sensing receptor. 
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2. Introduction 
GPR39-1a, a full length product of the GPR39 gene, is one of the rhodopsin type G 
protein-coupled receptors (GPCRs). It is classified as a member of the ghrelin receptor family 
based on similarities in amino acid sequence (3). This family consists of ghrelin, motilin, and 
neurotensin  receptors (3). Because each of these family members has important functions, 
especially in the gastrointestinal (GI) tract, it is expected that GPR39-1a may similarly play 
roles in the digestive system. Nevertheless, the function of GPR39-1a was completely 
unknown until recently, because its endogenous ligand had remained unidentified following its 
first cloning in 1997 (5).  
In 2004, Holst et al. (3) reported that GPR39-1a is constitutive active in both IP3 
accumulation and serum responsive element (SRE) activation. More recently, Zhang et al. 
identified a novel peptidergic hormone, obestatin, from rat stomach (6). This 
preproghrelin-derived 23-amino-acid peptide reportedly suppresses food intake, and acts as an 
endogenous ligand of GPR39-1a. The concentration of obestatin in serum is extremely low and 
below efficacious levels, though it is present in sufficient amounts to activate GPR39-1a in the 
stomach, the organ that produces it (6). Since GPR39-1a is expressed not only in the GI tract 
but in many other peripheral and central tissues (5, 7), it would not be surprising if other 
endogenous ligands for it existed. Moreover, several reports that obestatin dose not affect 
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GPR39-1a have very recently been published (8 - 11).  
I therefore searched for non-obestatin ligands from serum extracts. Considering both 
availability and reproducibility, commercialized fetal bovine serum (FBS) was chosen as a 
starting material. Because the endogenous ligands of GPR39-1a are expected to be peptidergic, 
the isolation procedure was based on a method for extraction of peptides (12) with some 
modifications to handle serum (13).  
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3. Materials and Methods 
3.1. Cloning of GPR39-1a genes 
Full-length cDNAs of human and mouse GPR39-1a (hGPR39-1a and mGPR39-1a, 
respectively) were obtained by ligations of the two exons amplified by PCR from genomic 
DNAs, while one of rat GPR39-1a (rGPR39-1a) was obtained by reverse transcriptase-PCR 
(RT-PCR) from first-strand cDNA of rat liver. The primers for hGPR39-1a were designed 
based on the reported mRNA sequence (accession number: NM_001508 in National Center for 
Biotechnology Information; http://www.ncbi.nlm.nih.gov/), while those for mGPR39-1a and 
rGPR39-1a were designed based on the sequences predicted by homology searches with 
hGPR39-1a against mouse or rat genomic DNAs. Each amplified DNA was ligated into 
pCDNA3.1 vector (Invitrogen, Grand Island, NY) and fused with the signal peptide 
MSALLILALVGAAVA of preprotrypsin (14) and a FLAG-tag in the N-terminal. 
 
3.2. Stable expression of hGPR39-1a  
The expression vector signal-FLAG-hGPR39-1a-pCDNA3.1 was transfected into 
CHO-K1 cells. Stably expressing cells were selected in 600 mg/L Geneticin (Invitrogen) and 
cloned by the limiting dilution method. Expression of hGPR39-1a was confirmed by RT-PCR 
and western immunoblot with monoclonal ANTI-FLAG M2 antibody (Sigma-Aldrich, St. 
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Louis, MO). One of the clones, HC48, was chosen for use in the calcium mobilization assays 
because of its high expression, reactivity, and growth rate. 
 
3.3. Conditioning of peptide fraction from fetal bovine serum 
(FBS)  
Fetal bovine serum (Hyclone, South Logan, UT) was deproteinized by 1 M acetic 
acid (AcOH) and 40% ethanol, followed by centrifugal separation at a rate of rotation of 5,000 
rpm for 30 min. The supernatant was filtered with a Minisette Omega 10K 10 KDa cut-off 
ultrafilter (Filtron Technology Corp., Northborough, MA). The filtrate was loaded onto a Mega 
Bond Elut
Flash
 C18 reverse-phase column (Varinan inc., Palo Alto, CA) pre-equilibrated in 10% 
acetonitrile and 0.1% trifluoroacetic acid (TFA). The absorbate was eluted in 60% acetonitrile 
containing 0.1% TFA after washing with 10% acetonitrile containing 0.1% TFA. The eluate 
was evaporated, and the residual material was redissolved in 1 M AcOH. This portion was 
designated the peptide fraction and subjected to ligand searches. 
 
3.4. Fractionation with cation-exchange (CE) column.  
The peptide fraction from FBS was separated by high performance liquid 
chromatography (HPLC) on the AKTA explorer 10S system (GE Healthcare, Piscataway, NJ) 
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with a Mini S PE 4.6/50 cation-exchange (CE) column (GE Healthcare). A gradient was 
provided at a flow rate of 500 μL/min by changing the mixing ratio of two eluents: A, 1M 
AcOH and B, 1M AcOH containing 1M NaCl. The proportion of B was initially 0% and 
increased to 50% over 16.6 min. The activity of each fraction was monitored by calcium 
mobilization in HC48, a cell line stably expressing hGPR39-1a. In this assay, an aliquot of 
each fraction equivalent to 10 mL serum was evaporated, redissolved and added to the cells 
suspended in a total volume of 50 μL buffer. Each of the components was thus condensed by 
200-fold of the yield. 
 
3.5. Fractionation with multi-mode (MM) column 
The active fraction was further fractionated by HPLC on an AKTA explorer 10S with 
a TSKgel VMpak-25 multi-mode (MM) column (Tosoh, Tokyo, Japan), which has both 
reverse-phase and cation-exchange characteristics. A gradient was provided at a flow rate of 
500 μL/min by changing the mixing ratio of two eluents: A, 10% (v/v) acetonitrile containing 9 
mM ammonium acetate - NaOH (pH 9.0) and B, 80% (v/v) acetonitrile containing 0.05% TFA. 
The proportion of B was initially 20% and increased to 91.4% in 33.2 min. The activity of each 
fraction was monitored by calcium mobilization in HC48. The tested amount of an aliquot in 
the assay was the same as for CE. 
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3.6. Calcium mobilization assays  
Cells were grown in DMEM/F12 (Invitrogen) supplemented with 10% FBS. After 
depletion of serum for 5 hours, cells were harvested by 0.025% Trypsin-EDTA (Invitrogen) 
and loaded with 4 μM Fluo-3AM (Molecular Probes, Inc., Eugene, OR) for 1 hour in assay 
buffer (Hank's balanced salt solution supplemented with 10 mM HEPES, 2.5 mM probenecid, 
and 0.1% BSA). After loading, cells were washed twice with assay buffer and plated at 2.0 × 
10
4 
cells/well in half-area clear-bottom black plates (Coring Corstar Co., Cambridge, MA). 
Intracellular calcium ion was detected by monitoring of fluorescence of 540 nm with excitation 
at 480 nm on the Functional Drug Screening System 6000 (Hamamatsu Photonics KK, 
Hamamatsu, Japan). The fluorescence intensity of each sample was recorded every 1.095 
seconds for about two minutes, with the tested samples added 10.95 seconds after the 
beginning of measurements. For each tested sample, I calculated the maximum fluorescence 
ratio over the baseline during two minutes, and considered it the intensity of calcium response. 
To detect GPR39-1a-specific activity, the intensity of each fraction was compared with that 
measured with the host cells, CHO-K1, in the same fashion. 
 
3.7. Determination of metal concentrations 
An aliquot of the purified fraction equivalent to 200 mL FBS was evaporated and 
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redissolved in 10 mL of 1% nitric acid. I examined the solution by inductively coupled plasma 
mass spectrometry (ICP-MS) to determine the concentrations of Zn, Cu, Mg, Fe, Mn, Cr, and 
Se. The concentration of each metal was calculated from the intensity of each m/z value with 
the calibration curve determined using the ICP multi-element standard solution IV (Merck 
KGaA, Darmstadt, Germany). These measurements were performed on the ICPM-8500 system 
(Shimadzu, Kyoto, Japan). 
 
3.8. Transient expressions of GPR39-1a genes 
CHO-K1 cells were plated on 100 mm-diameter culture dishes at 1.5 × 10
6 
cells/dishes on the day before transfection. Transfection was performed by the lipofection 
method using Lipofectamine2000 (Invitrogen). The amount of transfected vector was 12 μg 
per one dish. The cells were subcultured the following day, and used for calcium assays on the 
third day after transfection. 
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4. Results 
4.1. Finding of active fraction by cation-exchange HPLC 
First, the peptide fraction conditioned from FBS was fractionated by cation-exchange 
(CE) HPLC. An aliquot of each fraction was subjected to calcium mobilization assay with 
HC48, the cell line stably expressing human GPR39-1a (hGPR39-1a), and CHO-K1, the host 
cell. Strong activities specific to HC48 were found in the fractions eluted from 17.5 to 17.9 
min (total flow volume of 8.7 mL to 8.9 mL) (Fig. 2a, b). This finding indicates that 
GPR39-1a-activating components are contained in FBS and positively charged. The active 
fractions obtained by CE HPLC were pooled and processed by further fractionation to enable 
purification. 
 
4.2. Purification of the active fraction 
I examined several types of HPLC for use in the next step of fractionation, and 
finally chose a multi-mode (MM) column with both reverse-phase and cation-exchange 
properties. With this type of HPLC, activities were clearly detected in the fractions eluted 
around 40.8 min (total flow volume of 20.4 mL) (Fig. 3a, b), which corresponded to the 
inflection point on the conductivity curve. This finding suggests that the active components 
were absorbed in the column in the starting condition, and were eluted by the acute change in 
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conductivity. In the calcium mobilization assays, these fractions exhibited quick, transient 
increases in intracellular calcium in HC48 alone (Fig. 3c), indicating the presence of specific 
agonists of GPR39-1a coupling to Gqα or Giα. Presuming these fractions to be purified, I 
pooled and processed them for mass spectroscopy (MS) measurements. 
 
4.3. Identification of endogenous agonist of GPR39-1a as Zn
2+
 
ion 
Because the active constituent was expected to be a peptidergic molecule, MS and 
MS/MS measurements on the purified fraction were performed. However, no m/z values 
assignable to peptides were detected. This finding indicates that the active molecule is not a 
peptide, or that its concentration was below the limit of detection. Next, I considered the 
possibility of metal ions. Indeed, Holst et al. had previously shown that Zn
2+
 ion enhances IP3 
accumulation in GPR39-1a-expressing cells (1, 8). To examine this possibility, I re-assayed the 
purified fraction mixed with EDTA. The activity was eliminated by 300 nM of EDTA (Fig. 3c). 
This finding suggests that some types of metal ion are included and play critical roles in the 
active molecule. 
I therefore performed inductively coupled plasma mass spectrometry (ICP-MS) on 
the purified fraction to measure the contents of metals. 7.5 ppb of Mg, 49.2 ppb of Cu, and 
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191.3 ppb of Zn were detected in the 20-fold-concentrated purified fraction (Table 1), 
corresponding to 3.1 M, 7.8 M, and 29.0 M respectively, in the calcium assay systems. 
 
4.4. Responsiveness of GPR39-1a against divalent metal ions 
In order to determine whether the activity of the purified fraction was due to any of 
these metals, I tested the activities of ZnCl2, CuSO4, and MgCl2 by calcium mobilization assay 
with HC48 (Fig. 4a-d). Both ZnCl2 and CuSO4 were found to have concentration-dependent 
activities specific to HC48, while MgCl2 exhibited no activity in either HC48 or CHO-K1 cells. 
The potency of CuSO4 for HC48 was not sufficient to explain the activity of the purified 
fraction, since more than 100 M Cu (II) ion would be needed to exhibit activity equal to that 
of the purified fraction. On the other hand, the potency of ZnCl2 for HC48 is consistent with 
the amount measured in the purified fraction. The activity of the fraction was compared with 
ZnCl2 activity between 10 and 100 μM. The Zn detected in the purified fraction was found to 
be equivalent to 29 μM, and within this range. I therefore concluded that the isolated active 
constituent in this study is Zn
2+
 ion. 
 
4.5. Characterization of signaling pathway of GPR39-1a 
I then tested the inhibitory effects of pertussis toxin (PTx) and a phospholipase C 
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(PLC) inhibitor, U73122, to determine whether this activity is mediated through Gqα or Giα. 
The activity of ZnCl2 was abolished by U73122, while no inhibitory effects were observed 
with PTx (Fig. 4e). This finding indicates that the calcium-mobilizing activity of Zn
2+
 is 
mediated through the Gqα-PLC pathway.  
Finally, I tested ZnCl2 activity with cells transiently expressing mouse and rat 
GPR39-1a (mGPR39-1a and rGPR39-1a, respectively). Like hGPR39-1a, mGPR39-1a and 
rGPR39-1a were each also activated by both ZnCl2 and CuSO4 with quick, transient increases 
in intracellular calcium (Fig. 5a, b). These findings indicate that the function of GPR39-1a as a 
Zn(II)-sensing
 
receptor is conserved in rodents, as well. 
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5. Discussion 
In this chapter, I attempted to find natural agonists of GPR39-1a in FBS, using 
intracellular calcium mobilization as an index. To accomplish this, I performed two types 
of HPLC, cation-exchange (CE) and multi-mode (MM), on the peptide fraction 
conditioned from FBS. The active constituent was isolated, purified, and finally 
identified as Zn
2+
 by ICP-MS. In addition, I showed that the calcium-mobilizing activity 
of GPR39-1a is mediated through Gqα, using PTx and a PLC inhibitor. I also showed 
that the function of GPR39-1a as a Zn
2+
-sensing receptor is preserved across species, by 
assays with mGPR39-1a and rGPR39-1a. In discussing my findings, I consider the 
following three issues. 
The first is that Zn
2+
, the agonist of GPR39-1a, was isolated from peptide fraction of 
FBS, indicating that it was absorbed by the reverse-phase column in the conditioning phase. Of 
course, free Zn
2+
 ion itself is not absorbed by reverse-phase columns. Zn
2+
 probably formed 
complexes with carrier molecules (with molecular weight less than 10KDa) in the 
reverse-phase step, and dissociated from the carriers at some point in the following steps. Two 
considerations are suggested by the properties of Zn
2+
: one is the conditions of elution by NaCl 
gradient in CE, while the other is the starting buffer (pH 9.0, as titrated by NaOH) of MM. In 
these conditions, sodium ion is present in high concentration, and may replace Zn
2+
 bound to 
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the carrier molecules. 
  Second, I found only Zn2+ in the peptide fraction of FBS. While I pretreated serum 
with acetic acid and ethanol followed by ultrafiltration to remove high-molecular-weight 
proteins, I assume that serious loss of peptides did not occur with this method. Indeed, I found 
active fractions for angiotensin 1A receptor in a pilot study with the peptide fraction 
conditioned in the same fashion (data not shown). These findings suggest that there are no 
peptidergic molecules in FBS to activate GPR39-1a, or that, even if such molecules exist, their 
concentrations are extremely low. 
Third, GPR39-1a functions as a Gq-coupled Zn
2+
-sensing receptor, and this function 
is conserved across species. Consistent with previous reports (1, 8, 9), I found that Zn
2+
 acts as 
an agonist at GPR39-1a, inducing quick, transient increase in intracellular calcium. This 
activity was not abolished by PTx, but was by a PLC inhibitor, indicating that it is mediated 
through the Gqα-PLC pathway. The agonistic activities of Zn
2+
 at GPR39-1a were observed 
with both mouse and rat GPR39-1a. This finding indicates that the reactivity of GPR39-1a to 
Zn
2+
 is not limited to humans, but is present in rodents as well. The function of GPR39-1a as a 
Zn
2+
-sensing receptor is thus likely to be physiologically significant. 
Several findings have been reported suggesting the existence of extracellular 
Zn
2+
-sensing receptors in cells in a variety of tissues (15 - 19). Because the concentrations of 
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Zn
2+ 
ion efficacious for those receptors, reportedly 10-100 μM, are consistent with those for 
GPR39-1a, it is possible that GPR39-1a corresponds to some of those receptors. The salient 
question now is that whether the concentrations of Zn
2+
 ion present in vivo are sufficient to 
activate GPR39-1a. In one peripheral organ, the pancreas, about 20 mM of Zn is contained in 
secretion vesicles of the islets of Langerhans (20), and is released together with insulin (21). In 
the central nervous system (CNS) , the existence of free zinc ions is observed in synaptic 
vesicles of the hippocampus and other structures (22, 23). In addition, it has been reported that 
the concentration of zinc ion sometimes rises to 100-300 μM in synaptic clefts (24, 25). These 
locally and temporally restricted increases in Zn
2+
 concentrations are sufficient to activate 
GPR39-1a. In other organs, where no such high concentrations of Zn
2+
 release have been 
detected, serum is a potential source of Zn
2+
. Indeed, the total content of Zn in FBS is about 30 
μM (26), while that in serum of experimental animals and humans is reportedly 10-20 μM (27, 
28, 29). Regulation of Zn
2+
 concentration through the bloodstream thus appears to be of 
importance in modulating the function of GPR39-1a in many peripheral organs. 
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6. Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Fractionation of the peptide fraction of FBS by cation-exchange HPLC. a, Cation-exchange 
HPLC of the peptide fraction conditioned from FBS. The gradient profile is expressed as the mixing 
ratio of eluent B (broken line). Absorbance at 254 nm is indicated by the solid line. b, 
Calcium-mobilizing activity of each fraction assayed with HC48 (▲) and CHO-K1 (●). Tested aliquots 
were equivalent to 10 mL FBS in assay systems with a total volume of 50 L. The intensity of each 
fraction is represented by the maximum fluorescence ratio over the baseline during two minutes of 
assay time. 
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Fig. 3 Purification of the active fractions by multi-mode HPLC. a, Multi-mode HPLC of the active 
fraction isolated by cation-exchange. The gradient profile is expressed as the mixing ratio of eluent B 
(broken line). Absorbance at 254 nm is indicated by the solid line. Electrical conductivity is indicated 
by the dotted line.  b, Calcium-mobilizing activity of each fraction assayed with HC48 (▲) and 
CHO-K1 (●). Tested aliquots were equivalent to 10 mL FBS in assay systems with a total volume of 
50 L. The intensities of each fraction are represented by the maximum fluorescence ratio over the 
baseline during two minutes of assay time. c, Time course of intracellular calcium mobilization in 
HC48 cells stimulated by the purified fraction. Activity is expressed as the 540 nm fluorescence ratio 
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over the baseline with excitation at 480 nm. Total time of measurement is about two minutes. Samples 
are added to the assay systems at the time point indicated by the arrow. The activities of aliquots 
equivalent to 10 mL FBS, 1 mL FBS, and 10 mL FBS mixed with 300 nM EDTA are indicated by the 
solid line, the broken line, and the dotted line respectively. 
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Fig. 4 Calcium-mobilizing activities of Zn, Cu, and Mg ions with HC48. a-c, Dose-response curves for 
HC48 (▲) and CHO-K1 (●) treated with ZnCl2 (a), CuSO4 (b), and MgCl2 (c). Each of the activities is 
expressed as the maximum value of the 540 nm fluorescence ratio over the baseline during the 
two-minute period of measurement. Values are the means and S.E. obtained from 5-6 separate 
measurements. d, Time course of intracellular calcium mobilization in HC48 cells stimulated by 100 
M of ZnCl2 (solid line), CuSO4 (broken line), and MgCl2 (dotted line). Each of the activities is 
expressed as the 540 nm fluorescence ratio over the baseline with excitation at 480 nm. Total time of 
measurement is about two minutes. Samples are added to the assay systems at the time point indicated 
Log[MgCl2](M) 
Log[ZnCl2](M) 
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by the arrow. e, Effects of PTx and U73122 on the activity of ZnCl2. Increases in intracellular calcium 
concentration of HC48 were measured with stimulation by 100 M ZnCl2. Cells were pretreated with 
100g/mL PTx or 10M U73122. PTx was added to the cells on the day before assay, while U73122 
was added about ten minutes prior to measurements. Values are the means and S.E. of maximum 
fluorescence ratio obtained with 5-6 separate measurements. 
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Fig. 5 Preservation of function of GPR39 across species. Time course of intracellular calcium 
mobilization with CHO-K1 cells transiently expressing mGPR39 (a) or rGPR39 (b) treated with 
100M of ZnCl2 (solid line) or CuSO4 (broken line). Samples are added to the assay systems at the 
time point indicated by the arrows.
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CHAPTER Ⅲ. GPR39-1b INTERACTS WITH 
NEUROTENSIN RECEPTOR NTSR1 AND 
MODIFIES ITS FUNCTION 
 
1. Summary  
In this chapter, the molecular functions of GPR39-1b were explored in cell 
culture. In contrast to GPR39-1a, GPR39-1b showed no response to Zn
2+
 stimulation in 
calcium mobilization assays, suggesting that GPR39-1b is not a functional receptor of 
Zn
2+
. To understand the signaling interaction of GPR39-1b, the dimerization between the 
isoforms was investigated, and bioluminescence resonance energy transfer (BRET
2
) 
assays were conducted. The results indicated that GPR39-1b homodimerized, but did not 
heterodimerize with GPR39-1a. Subsequently, searching the heterodimeric counterparts 
of GPR39-1b was attempted. Neurotensin receptor 1 (NTSR1) was also targeted as a 
GPR39-1b interacting partner because of its highly conserved amino acid sequence and 
mRNA localization, which was similar to GPR39-1b. BRET
2
 assays demonstrated that 
GPR39-1b heterodimerized with NTSR1. To examine the effect of GPR39-1b on 
NTRS1-mediated cAMP/PKA signaling, the cAMP responsive element-luciferase assays 
was demonstrated, and it was observed that GPR39-1b attenuated neurotensin-induced 
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NTSR1 signaling. Taken together, the results in this chapter provided a novel regulatory 
mechanism for GPR39-1b in NTRS1 signaling. 
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2. Introduction 
 Most of the receptors in the ghrelin receptors family are involved in the 
regulation of metabolism and nutrition uptake. GHSR is expressed in the brain and 
stomach and functions as the cognate receptor of ghrelin, an appetite-inducing hormone 
(2). NTSR1, NTSR2, and GPR38 are expressed in the small intestine and works as the 
receptors of the hormones controlling intestinal motility and fecal transit, neurotensin 
(NTS) and motilin (5,30). It is expected that GPR39 also has physiological roles in energy 
metabolism because GPR39 null mice showed abnormalities such as obesity (31), altered 
glucose tolerance (31, 32), pancreatic malfunctions (33-35), and accelerated gastric 
emptying (36-38). 
GPR39 is known to encode two isoforms, GPR39-1a and -1b (4). GPR39-1a is a 
full-length 7-transmembrane receptor, which is primarily expressed in the liver, stomach, 
and pancreas. As shown in the Chapter Ⅱ, GPR39-1a serves as a receptor of Zn2+ ion and 
mobilizes intracellular calcium. According to the reports from another group, the 
intracellular signaling of GPR39-1a is mediated by cAMP increase and extracellular 
signal-regulated kinase (ERK) phosphorylation as well (3,40). In the pancreas, it is 
thought that GPR39-1a is activated to regulate insulin secretion in response to a transient 
increase in extracellular Zn
2+
. Extracellular Zn
2+
 level elevations are rare in the other 
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tissues except the brain (24, 25). Considering the broad tissue distribution, GPR39-1a 
may have biological roles other than Zn
2+
-sensing receptor. On the other hand, GPR39-1b 
is a truncated 5-transmembrane isoform of GPR39, composed of the extracellular 
N-terminal and 1st-5th transmembrane domains (TMI-V) (4). GPR39-1b is expressed 
primarily in the stomach and small intestine, but its molecular function, including Zn
2+ 
binding, remains unknown.  
GHSR-1b, the 5-transmembrane isoform of GHSR, interacts with the full-length 
isoform GHSR-1a to attenuate ghrelin-activated signaling (41). In another case, 
artificially truncated forms of NTSR2 heterodimerize with NTSR1 and inhibit NTS 
signaling (42). These suggest that direct interaction between GPCRs or its isoforms is 
physiologically important. However, the physiological significance of GPR39-1b and 
GPR39-1a or other homologous receptors interactions are unclear. In the present study, 
the molecular characteristics of GPR39-1b were investigated to understand the regulatory 
role of GPR39-1b in intracellular signaling by the functional association with GPCRs. 
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3. Materials and Methods 
3.1. Cloning of genes 
Cloning of GPR39-1a was described in the ChapterⅡ. GPR39-1b, NTSR1, and 
GRP109a were cloned using polymerase chain reaction (PCR) from human genomic DNA. 
For functional assays, expression vectors of these genes were obtained by subcloning 
them into the pCDNA3.1 vector (Life technologies, Carlsbad, CA). Expression vectors of 
donor and acceptor for BRET
2
 assays (43) were obtained by subcloning the GPCR genes 
into pRluc-N and pGFP2-N protein fusion vectors (Perkin Elmer, Waltham, MA), 
respectively. The cAMP responsive element-luciferase (CRE-Luc) reporter gene was 
obtained by subcloning six consecutive CRE sequences, the promoter of the vasoactive 
intestinal polypeptide (VIP) gene (44), and the luciferase gene into pGL3 vector 
(Promega Co., Madison, WI). The promoter of VIP was inserted into the position between 
the 6CREs and the luciferase gene in order to magnify the signal. 
 
3.2. Calcium mobilization assays 
CHO-K1 cells (American Type Culture Collection) and HC48 cells, a 
CHO-K1-based cell line stably expressing GPR39-1a already reported in described in the 
ChapterⅡ, were grown in DMEM/F12 (Life technologies) supplemented with 10% fetal 
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bovine serum (FBS). Cells were harvested with 0.025% Trypsin-EDTA (Life 
technologies) and loaded with 4 μM Fluo-3AM (Molecular Probes, Inc., Eugene, OR) for 
1 h in assay buffer (Hank’s balanced salt solution supplemented with 10 mM HEPES, 2.5 
mM probenecid, and 0.1% BSA). After loading, cells were washed twice with assay 
buffer and plated at 2.0 × 10
4 
cells/well in half-area 96-well clear-bottom black plates 
(Coring Costar Co., Cambridge, MA). Intracellular calcium ion content was detected by 
monitoring fluorescence at 540 nm with excitation at 480 nm on a Functional Drug 
Screening System 6000 (Hamamatsu Photonics KK, Hamamatsu, Japan). For each sample 
tested, the maximum fluorescence:baseline intensity ratio was calculated over 2 min; this 
was considered the intensity of calcium response. 
 
3.3. CRE-luciferase reporter assays 
HEK293 cells (American Type Culture Collection) were grown in DMEM (Life 
technologies) supplemented with 10% FBS. Cells were transfected with the CRE-Luc 
reporter gene, described above, together with GPCRs. The following day, cells were 
harvested by 0.025% trypsin-EDTA (Life technologies), washed once with assay buffer 
(OPTI-MEM supplemented with 0.1% BSA), and plated at 5 × 10
4
 cells/well in 96-well 
white plates (Coring Costar Co., Cambridge, MA). Plates were filled with assay buffer 
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with  NTS at 1, 0.1, and 0.01 M as the final concentration and incubated for 5 h at 37°C. 
After the incubation, Steady-Glo (Promega Co.) diluted with lysis buffer (10% SDS-PBS) 
was added to the cells. Sample luminescence was measured by ARVO-SX (Perkin Elmer). 
 
3.4. BRET
2
 assays 
BRET
2
 (43) was modified from BRET by replacing yellow fluorescence protein 
(YFP), the acceptor protein, with green fluorescence protein2 (GFP2). The donor vector 
pRluc-N, containing a GPCR fused to Rluc (Renilla luciferase), and the acceptor vector 
pGFP2-N, containing a GPCR fused toGFP2, were prepared as described above. HEK293 
cells were plated at 2 × 10
4
 cells/well in 96-well collagen coated plate (Corning Costar) 3 
days before the assay. The following day, donor (0, 10, 20, 40, 60, 80, and 100 ng/well) 
and acceptor (50 ng/well) vectors were co-transfected into the HEK293 cells and 
incubated overnight. At the day of the assay, cells were washed once and filled with 40 
L of assay buffer (D-PBS supplemented with 0.15% glucose, 1 mM MgCl2, 1 mM CaCl2, 
and 2 g/mL of aprotinin). After 10 L of 25 mol/L DeepBlueC (Perkin Elmer) was 
added, the fluorescence intensity at 410 nm and 515 nm were measured to determine the 
activity of Rluc and the signal caused by BRET
2
, respectively. The 515 nm fluorescence 
raised by 405 nm laser was also measured by ARVO light (Perkin Elmer) to determine the 
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basal level of GFP2 fluorescence. The BRET
2
 signal was calculated by the equation 
below. 
BRET
2
 signal = (Emission at 515 nm - Emission at 515 nm of non-transfected cells) 
/ (Emission at 410 nm - Emission at 410 nm of non-transfected cells) 
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4. Results 
4.1. Calcium mobilization assays in the cells transfected 
with GPR39-1b 
Calcium mobilization assays were performed to determine if GPR39-1b alone 
acts as a Zn
2+
 receptor. In HC48 cells, a CHO-K1-based cell line stably expressing 
GPR39-1a, ZnCl2 induced the mobilization of intracellular calcium (Fig. 6a, square). In 
contrast, GPR39-1b transfected CHO-K1 cells did not mobilize intracellular calcium in 
response to ZnCl2 (Fig. 6b, triangle) compared with that in non-transfected cells (Fig. 1b, 
square). This result indicated that GPR39-1b is not a functional receptor for Zn
2+
. To 
investigate the effect of GPR39-1b on GPR39-1a signaling, HC48 cells were transfected 
with GPR39-1b and stimulated with ZnCl2. GPR39-1b transfection did not affect the 
ZnCl2-induced intracellular calcium mobilization mediated by GPR39-1a (Fig. 6a, 
triangle). 
 
4.2. BRET
2
 assays to evaluate the homodimerization and 
heterodimerization across the isoforms of GPR39 gene 
BRET
2
 assays were carried out to evaluate the physical interactions between 
GPR39 isoforms. Various amounts of GPR39-1a-GFP2 vector were co-transfected into 
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HEK293 cells along with the GPR39-1b-Rluc vector, and the fluorescence signal was 
measured after the addition of the Rluc substrate. BRET
2
 was not observed between 
GPR39-1a-GFP2 and GPR39-1b-Rluc (Fig. 7a). However, under identical condition, 
GPR39-1b-GFP2 and GPR39-1b-Rluc showed BRET
2
 (Fig. 7b). These results indicated 
that GPR39-1b homodimerized, but did not heterodimerize with GPR39-1a. 
 
4.3. BRET
2
 assays to explore the heterodimeric counterpart 
of GPR39-1b 
It was assumed that GPR39-1b exerted its functions by interacting with other 
GPCRs, and the heterodimeric counterparts of GPR39-1b was explored using the BRET
2
 
system. Heterodimerization tends to occur between structurally homologous receptors 
(45), and receptor co-localization is an important physiological factor with regard to their 
physical interactions. NTSR1 is a member of the ghrelin receptor family and structurally 
homologous to GPR39-1b (3). Moreover, similar to GPR39-1b, NTSR1 is expressed in 
the brain and small intestine (4, 46). GPR109a, a class A orphan GPCR is expressed in the 
colon and small intestine (47), like as GPR39-1b. Thus, NTSR1 and GPR109a were 
chosen as candidate GPR39-1b heterodimerization partners. NTSR1 and GPR109a were 
fused with Rluc to construct the donor vector for the BRET
2
 system and co-transfected 
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into HEK293 cells with various amounts of the acceptor vector GPR39-1b-GFP2. As 
shown in Fig. 3a, BRET
2
 between NTSR1-Rluc and GPR39-1b-GFP2 exhibited a 
saturation curve that depended on the GPF2:Rluc ratio with a non-linear equation. This 
result indicated that GPR39-1b heterodimerized with NTSR1. The interaction of these 
receptors was confirmed by swapping donor and acceptor (Fig. 8c). On the other hand, 
co-transfection with GPR109-Rluc and GPR39-1b-GFP2 did not result in a BRET
2
 signal 
(Fig. 8b), indicating no interaction. 
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4.4. CRE-Luc assays to evaluate the functional effects of 
heterodimerization on the signaling activity of NTSR1 
It is presumed that cAMP signaling is important for the NTSR1-mediated 
regulation of Cl
−
 secretion by the small intestine. Therefore, I focused on 
NTSR1-mediated cAMP signaling. The functional role of GPR39-1b:NTSR1 
heterodimerization in NTSR1 signaling was examined using CRE-Luc reporter gene 
assays. CRE-Luc, NTSR1, and varying amounts of GPR39-1b vectors were transfected 
into HEK293 cells. As shown in Fig. 9, the NTS-triggered luminescence signal was 
attenuated depending on the amounts of GPR39-1b transfected. This result indicated that 
GPR39-1b and NTSR1 heterodimerization inhibited NTSR1-mediated cAMP/PKA 
signaling. To confirm that NTSR1 expression levels were not altered, fluorescence was 
measured in HEK293 cells co-transfected with NTSR1-GFP2 and GPR39-1b. The 
fluorescence intensity evoked from NTSR1-GFP2 was not affected by the amount of 
GPR39-1b transfected, indicating that GPR39-1b did not interfere with NTSR1 
expression (Fig. 10). 
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5. Discussion 
Recently, truncated isoforms of some GPCRs have been identified (41, 48, 49). 
However, their functions of most of them are still unclear. In this study, the molecular 
function of one of such molecules, GPR39-1b was explored. 
GPR39-1b contains an extracellular Zn
2+
 binding domain, but lacks the 
intracellular domains that interact with heterotrimeric G proteins (40). Therefore, it is 
assumed that GPR39-1b does not have functions to transduce extracellular signals into the 
cells even if it can bind to Zn
2+
 ions. In this study, calcium mobilization assays 
demonstrated that GPR39-1b was nonresponsive to ZnCl2. BRET
2 
assay demonstrated 
that GPR39-1b homodimerized, but did not heterodimerize with GPR39-1a. In addition, it 
was confirmed that GPR39-1b did not modulate the calcium mobilizing activity of 
GPR39-1a. This is not the case of GHSR-1b, a short isoform of the GHSR gene 
translation product. GHSR-1b heterodimerizes with and modifies the signaling activity of 
GHSR-1a, a full-length isoform (41). 
It was hypothesized that GPR39-1b works by heterodimerizing with other 
GPCRs similar in amino acid sequence and tissue distribution. The results indicated that 
NTSR1, the NTS receptor, heterodimerized with GPR39-1b. In particular, CRE-Luc 
reporter gene assays showed that GPR39-1b suppressed the NTSR1-mediated 
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cAMP/PKA-signaling pathway. NTSR1 signaling interference was previously reported 
for NTSR2, a subtype of NTSR1 (42). NTSR2 regions important for the attenuation of 
NTSR1 signaling are identified to be TM I-IV because the strongest suppression was 
shown by the NTSR2 mutants lacking TM V-VII and the C-terminal intracellular domain. 
Because GPR39 shares sequence similarities with NTSR2, the GPR39-1b-associated 
inhibition of NTSR1 signaling may have a similar mechanism.  
NTSR1 couples to both Gq and Gs to increase intracellular calcium and cAMP, 
respectively (30). The Gs/cAMP signal is involved in Cl
−
 release from the epithelium of 
the small intestine and colon (50, 51) where NTS treatment evokes Cl
−
 secretion and 
accelerates fecal transit in the gastrointestinal tract (52, 53). As described above, NTSR2 
inhibit NTSR1 signaling (42), but NTSR2 is mostly expressed in the brain (54). Therefore, 
NTSR2 is unlikely involved in the regulation of intestinal Cl
−
 secretion and fecal transit. 
Considering that GPR39-1b repressed NTSR1 signaling, GPR39-1b may prevent Cl
−
 
secretion and delay fecal transit. Interestingly, it is reported that GPR39 null mice, 
lacking both GPR39-1a and GPR39-1b, exhibit accelerated fecal transit (36). This is 
consistent if GPR39-1b constitutively suppresses the NTSR1 signaling that promotes 
fecal excretion (55) and the loss of GRP39-1b increase defecation. GPR39 null mice also 
exhibit increased gastric emptying (36). This phenotype cannot be explained by 
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GPR39-1b inhibition of NTSR1 signaling because NTSR1 slows gastric emptying (56). 
In conclusion, the findings in this chapter highlighted a novel regulatory 
function of GPR39-1b in NTSR1 signaling. Recent reports showed that the brain 
GPR39-1b mRNA levels are greater than GPR39-1a mRNA levels (4), and the injection of 
antisense GPR39-1b into the rat brain induces anxiety (57). In any case, the molecular 
and physiological effects of GPR39-1b-mediated inhibition of NTSR1 signaling in the 
gastrointestinal tract, brain, and the other tissues still remain unrevealed. Further 
characterization is necessary in order to fully understand the physiological significance of 
GPR39-1b. 
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6. Figures and Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 Calcium-mobilizing activities of Zn
2+
 in cells transfected with GPR39-1b. 
Dose-response curves for HC48 (a) and CHO-K1 (b) cells treated with ZnCl2. Cells were 
transfected with GPR39-1b (▲) or control vector (■). Activities are expressed as the 
maximum value of the 540 nm fluorescence ratio over baseline during a 2-min 
measurement. Values are means ± standard error (SE) obtained from four individual 
measurements.  
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Fig. 7 BRET
2
 assays of GPR39 isoforms. 
GPR39-1b-Rluc was co-transfected into HEK293 cells with GPR39-1a-GFP2 (a) or 
GPR39-1b-GFP2 (b). Total luminescence and fluorescence were measured. BRET
2
 values 
were not increased according to the GFP2/Rluc ratio. The nonlinear regression equation 
did not converge, suggesting that GPR39-1a and GPR39-1b did not interact (a). For cells 
transfected with GPR39-1b-Rluc and GPR39-1b-GFP2, a saturation curve was obtained 
with a nonlinear regression equation that assumed a single binding site where R
2
 = 0.88 
(b).  
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Fig. 8 BRET
2
 assays of GPR39-1b with NTSR1 and GPR109a.  
GPR39-1b-Rluc was co-transfected into HEK293 cells with NTSR1-GFP2 (a) and 
GPR109a-GFP2 (b). Total luminescence and fluorescence were measured. For 
GPR39-1b-Rluc and NTSR1-GFP2, a saturation curve was obtained with nonlinear 
regression equation (R
2
 = 0.77). To confirm heterodimerization, the donor and acceptor 
were swapped. NTSR1-Rluc was co-transfected into HEK293 cells with GPR39-1b-GFP2 
(c). A saturation curve was obtained with a nonlinear regression equation (R
2
 = 0.62).  
 
 
 
 
 
 
 
 
 
 
 52 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9 Effects of GPR39-1b and NTSR1 co-expression on the NTS-CRE signal.  
GPR39-1b was transiently co-expressed with NTRS1 and the CRE-Luciferase reporter 
gene in HEK293 cells. Control are cells transfected with the CRE-Luc and empty vector. 
The amounts of DNA transfected are indicated in parentheses (g/2 × 106 cells). Each of 
the NTS-induced luciferase activities is expressed as luminescence. Values are means 
±SE obtained from three individual measurements. 
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Fig. 10 Effects of co-expression of GPR39-1b on NTSR1 gene transcription.  
GPR39-1b was transiently co-expressed in HEK293 cells with NTSR1-GFP2. Control are 
cells transfected with empty vector. The amounts of DNA transfected are indicated in the 
parentheses (g/6 × 106 cells). Each of the activities is expressed as fluorescence. Values 
are means ± SE obtained from 16 separate measurements. 
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CHAPTER Ⅳ. CONCLUDING REMARKS 
 
 In the present study, the molecular functions of two isoforms, GPR39-1a and 
GPR39-1b, encoded in the GPR39 gene, were characterized. 
 In the Chapter Ⅱ , GPR39-1a, the full-length 7-transmembrane isoform, whose 
ligands and functions had been unknown, was revealed as a Gq-coupled Zn
2+
-sensing receptor. It 
is known that Zn
2+
 ion has many bioactivities in the body, while their mechanisms are unclear. 
On the other hand, the physiological importance of GPR39 gene is being elucidated by 
genetically engineered models in several institutes. The findings of the present study may give a 
link between bioactivities of Zn
2+
 ion and the physiological roles of the GPR39 gene. 
 In the Chapter Ⅲ, a new molecular function of GPR39-1b, the truncated isoform, was 
discovered. GPR39-1b heterodimerized with NTSR1, a receptor of neurotensin, and inhibited its 
signaling activity. This means GPR39-1b may have a role to modulate the activity of 
neurotensin and to work as a regulator of gastrointestinal transit. This finding may explain one 
aspect of the physiological meaning of GPR39-1b in the GI tract. Moreover, this finding can 
shed light on the importance of the molecular functions of short isoforms of GPCRs. 
As described above, the present study newly elucidated molecular functions of the two 
isoforms of GPR39, GPR39-1a and GPR39-1b. These findings are expected to provide clues for 
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further understanding on the physiological roles of the GPR39 gene. 
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